Levent Kabasakal

List of Publications by Year
in descending order

69	1,810	331670 21	276875 41
papers	citations	h-index	g-index

69	69	69	2218
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Almost Complete Response with a Single Administration ²²⁵Ac-DOTATATE in a Patient with a Metastatic Neuroendocrine Tumor of Unknown Primary. Molecular Imaging and Radionuclide Therapy, 2022, 31, 139-141.	0.7	2
2	Prior therapies as prognostic factors of overall survival in metastatic castration-resistant prostate cancer patients treated with [177Lu]Lu-PSMA-617. A WARMTH multicenter study (the 617 trial). European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 113-122.	6.4	72
3	Consensus on molecular imaging and theranostics in neuroendocrine neoplasms. European Journal of Cancer, 2021, 146, 56-73.	2.8	120
4	Evaluation of F-18 DOPA PET/CT in the detection of recurrent or metastatic medullary thyroid carcinoma: comparison with GA-68 DOTA-TATE PET/CT. Annals of Nuclear Medicine, 2021, 35, 900-915.	2.2	18
5	The impact of the extent of the bone involvement on overall survival and toxicity in mCRPC patients receiving [177Lu]Lu-PSMA-617: a WARMTH multicentre study. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 4067-4076.	6.4	20
6	[68Ga]DOTA-FAPI-04 PET/CT imaging in a case of a signet ring cell carcinoma of stomach. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 4523-4524.	6.4	4
7	PET/CT in Treatment Response Evaluation of Colorectal Cancer. , 2021, 7, 241-245.		0
8	Ga-68 PSMA PET/CT in the Evaluation of Treatment Response in Prostate Cancer. , 2021, 7, 246-251.		0
9	Nuclear Imaging and Treatment of Pheochromocytoma and Paragangliomas. , 2021, 7, 293-299.		0
10	PRRT in NETâ€™s: Lu-177 PRRT and New Scope Alpha Treatment. , 2021, 7, 300-309.		0
11	Interobserver and intraobserver agreement on prostate-specific membrane antigen PET/CT images according to the miTNM and PSMA-RADS criteria. Nuclear Medicine Communications, 2020, 41, 759-767.	1.1	16
12	Therapyâ€related chronic myeloid leukemia in a patient receiving peptide receptor radionuclide therapy for pancreatic neuroendocrine tumor. Cancer Reports, 2020, 3, e1282.	1.4	3
13	Performance of F-18 Fluorocholine PET/CT for Detection of Hyperfunctioning Parathyroid Tissue in Patients with Elevated Parathyroid Hormone Levels and Negative or Discrepant Results in conventional Imaging. Korean Journal of Radiology, 2020, 21, 236.	3.4	17
14	Post-therapy imaging of 225Ac-DOTATATE treatment in a patient with recurrent neuroendocrine tumor. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 2711-2712.	6.4	15
15	Procedure Guidelines for Lu-177 PSMA Radyoligand Treatment. , 2020, 6, 385-396.		1
16	Guideline for the Treatment of Liver Cancer with Y-90 Radiomicrosphere. , 2020, 6, 416-422.		0
17	Practical Guidance on Peptide Receptor Radionuclide Therapy. , 2020, 6, 406-415.		0
18	Procedur Guideline for Prostate Cancer Imaging: Ga68 PSMA PET/CT. , 2020, 6, 370-384.		1

#	Article	IF	Citations
19	Guideline for PET/CT Imaging of Neuroendocrine Neoplasms with 68Ga-DOTA-conjugated Somatostatin Receptor Targeting Peptides. , 2020, 6, 397-405.		0
20	The Role of 68GA-PSMA PET/CT Scan In Patients with Prostate Adenocarcinoma who Underwent Radical Prostatectomy. Urology Journal, 2020, 18, 58-65.	0.4	2
21	Prognostic value of ADC measurements in predicting overall survival in patients undergoing 90Y radioembolization for colorectal cancer liver metastases. Clinical Imaging, 2019, 57, 124-130.	1.5	7
22	Can SUVmax values of Ga-68-PSMA PET/CT scan predict the clinically significant prostate cancer?. Nuclear Medicine Communications, 2019, 40, 86-91.	1.1	83
23	177Lu-DOTATATE therapy in patients with neuroendocrine tumours including high-grade (WHO G3) neuroendocrine tumours. Nuclear Medicine Communications, 2018, 39, 789-796.	1.1	53
24	Red bone marrow dose estimation using several internal dosimetry models for prospective dosimetry-oriented radioiodine therapy. Radiation and Environmental Biophysics, 2018, 57, 395-404.	1.4	7
25	ESTIMATION OF THE ORGAN ABSORBED DOSES AND EFFECTIVE DOSE FROM 68Ga-PSMA-11 PET SCANâ€. Radiation Protection Dosimetry, 2018, 182, 518-524.	0.8	8
26	MP20-15 THE ACCURACY OF 68GALLIUM-PSMA PET/CT IN PRIMARY LYMPH NODE STAGING FOR HIGH RISK PROSTATE CANCER. Journal of Urology, 2017, 197, .	0.4	0
27	The role of PSMA PET/CT imaging in restaging of prostate cancer patients with low prostate-specific antigen levels. Nuclear Medicine Communications, 2017, 38, 149-155.	1.1	32
28	The accuracy of 68Ga-PSMA PET/CT in primary lymph node staging in high-risk prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 1806-1812.	6.4	89
29	Abdominal Splenosis Mimicking Peritoneal Metastasis in Prostate-Specific Membrane Antigen PET/CT, Confirmed With Selective Spleen SPECT/CT. Clinical Nuclear Medicine, 2017, 42, e504-e505.	1.3	6
30	Lu-177-PSMA-617 Prostate-Specific Membrane Antigen Inhibitor Therapy in Patients with Castration-Resistant Prostate Cancer: Stability, Bio-distribution and Dosimetry. Molecular Imaging and Radionuclide Therapy, 2017, 26, 62-68.	0.7	53
31	Normal distribution pattern and physiological variants of 68Ga-PSMA-11 PET/CT imaging. Nuclear Medicine Communications, 2016, 37, 1169-1179.	1.1	126
32	Evaluation of radiation safety in¹⁷⁷Lu-PSMA therapy and development of outpatient treatment protocol. Journal of Radiological Protection, 2016, 36, 269-278.	1.1	39
33	Information about Prostate Cancer for Urologist: Ga-68 Prostate Specific Membrane Antigen Positron Emission Tomography/Computed Tomography Scintigraphy. Ãœroonkoloji BÃ¼lteni, 2016, 15, 159-162.	0.1	0
34	Long-Term Palliative Effect of Stenting in Gastric Outlet Obstruction Due to Transarterial Chemoembolization with Yttrium-90 in a Patient with Metastatic Neuroendocrine Tumor. Clinical Endoscopy, 2016, 49, 479-482.	1.5	0
35	Evaluation of PSMA PET/CT imaging using a 68Ga-HBED-CC ligand in patients with prostate cancer and the value of early pelvic imaging. Nuclear Medicine Communications, 2015, 36, 582-587.	1.1	125
36	Pre-therapeutic dosimetry of normal organs and tissues of 177Lu-PSMA-617 prostate-specific membrane antigen (PSMA) inhibitor in patients with castration-resistant prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2015, 42, 1976-1983.	6.4	166

#	Article	IF	Citations
37	Evaluation of Liver Stiffness After Radioembolization by Real-Time ShearWaveâ„¢ Elastography: Preliminary Study. CardioVascular and Interventional Radiology, 2015, 38, 957-963.	2.0	2
38	FDG and FDG-labelled leucocyte PET/CT in the imaging of prosthetic joint infection. European Journal of Nuclear Medicine and Molecular Imaging, 2014, 41, 556-564.	6.4	57
39	68Ga-PSMA PET/CT imaging of metastatic clear cell renal cell carcinoma. European Journal of Nuclear Medicine and Molecular Imaging, 2014, 41, 1461-1462.	6.4	127
40	Evaluation and comparison of Ga-68 DOTA-TATE and Ga-68 DOTA-NOC PET/CT imaging in well-differentiated thyroid cancer. Nuclear Medicine Communications, 2013, 34, 1084-1089.	1.1	22
41	Clinical value of technetium-99m-labeled octreotide scintigraphy in local recurrent or metastatic medullary thyroid cancers. Nuclear Medicine Communications, 2013, 34, 1190-1195.	1.1	5
42	Comparison of 99mTc-HYNIC-TOC and HYNIC-TATE Octreotide Scintigraphy With FDG PET and 99mTc-MIBI in Local Recurrent or Distant Metastatic Thyroid Cancers. Clinical Nuclear Medicine, 2013, 38, 321-325.	1.3	11
43	Comparison of Ga-68 DOTA-TATE and Ga-68 DOTA-LAN PET/CT imaging in the same patient group with neuroendocrine tumours. Nuclear Medicine Communications, 2013, 34, 727-732.	1.1	14
44	The Diagnostic Efficiency of 99mTc-EDDA/HYNIC-Octreotate SPECT-CT in Comparison with 111In-Pentetrotide in the Detection of Neuroendocrine Tumours. Molecular Imaging and Radionuclide Therapy, 2013, 22, 76-84.	0.7	11
45	The different distribution patterns of FDG and FDG-labelled WBC in inflammatory and infectious lesions. European Journal of Nuclear Medicine and Molecular Imaging, 2012, 39, 1660-1661.	6.4	4
46	Comparison of 68Ga-DOTATATE and 68Ga-DOTANOC PET/CT imaging in the same patient group with neuroendocrine tumours. European Journal of Nuclear Medicine and Molecular Imaging, 2012, 39, 1271-1277.	6.4	119
47	Influence of biological assay conditions on stability assessment of radiometal-labelled peptides exemplified using a 177Lu-DOTA-minigastrin derivative. Nuclear Medicine and Biology, 2011, 38, 171-179.	0.6	21
48	Intraoperative Localization of Recurrent Medullary Carcinoma of the Thyroid Using Tc-99m HYNIC-TATE and a Surgical Gamma Probe. Clinical Nuclear Medicine, 2011, 36, 831-833.	1.3	2
49	Sistatin C: bÃ¶brek iÅŸlevleri azalmakta olan Ã§ocuklarda glomerÃ¼ler filtrasyon hÄ±zÄ± Ã¶lÃ§Ã¼mÃ¼nde daha yararlÄ± bir deÄŸiÅŸken olabilir mi?. Turk Pediatri Arsivi, 2011, 46, 118-123.	0.9	0
50	Ectopic Parathyroid Adenoma Localized With MIBI Scintigraphy and Excised With Guide of Macroaggregated Human Serum Albumin Injection. Clinical Nuclear Medicine, 2010, 35, 151-153.	1.3	11
51	Intravascular radiation therapy with a Re-188 liquid-filled balloon in patients with in-stent restenosis. Nuclear Medicine Communications, 2010, 31, 746-752.	1.1	2
52	Temporal relationship between gastroesophageal reflux and rate of gastric emptying in children. Nuclear Medicine Communications, 2010, 31, 1059-1062.	1.1	11
53	Gastrinoma and Insulinoma in a Patient With Multiple Endocrine Neoplasia. , 2005, 15, 151-153.		1
54	Is the I-131 whole-body scanning proper for follow-up management of the patients with malignant struma ovarii without performing the thyroidectomy?. Gynecologic Oncology, 2005, 99, 520.	1.4	5

#	Article	IF	Citations
55	A dynamic renal phantom for nuclear medicine studies. Medical Physics, 2005, 32, 530-538.	3.0	14
56	Treatment of iodine-negative thyroglobulin-positive thyroid cancer: differences in outcome in patients with macrometastases and patients with micrometastases. European Journal of Nuclear Medicine and Molecular Imaging, 2004, 31, 1500-1504.	6.4	30
57	Guidelines for direct radionuclide cystography in children. European Journal of Nuclear Medicine and Molecular Imaging, 2003, 30, B39-B44.	6.4	34
58	Guidelines for radioiodinated MIBG scintigraphy in children. European Journal of Nuclear Medicine and Molecular Imaging, 2003, 30, B45-B50.	6.4	80
59	The effects of exposure of 60Co on the oxidant/antioxidant status among radiation victims. Journal of Environmental Radioactivity, 2003, 64, 19-25.	1.7	8
60	Is furosemide administration effective in improving the accuracy of determination of differential renal function by means of technetium-99m DMSA in patients with hydronephrosis. European Journal of Nuclear Medicine and Molecular Imaging, 2002, 29, 1433-1437.	6.4	5
61	Technetium-99m ethylene dicysteine: a new renal tubular function agent. European Journal of Nuclear Medicine and Molecular Imaging, 2000, 27, 351-357.	6.4	29
62	Correlation of technetium-99m MIBI and thallium-201 retention in solitary cold thyroid nodules with postoperative histopathology. European Journal of Nuclear Medicine and Molecular Imaging, 2000, 27, 713-720.	6.4	31
63	Ictal and interictal SPECT findings in childhood absence epilepsy. Seizure: the Journal of the British Epilepsy Association, 2000, 9, 265-269.	2.0	29
64	The Effect of P-Glycoprotein Function Inhibition With Cyclosporine A on the Biodistribution of Tc-99m Sestamibi. Clinical Nuclear Medicine, 2000, 25, 20.	1.3	12
65	Reproducibility of technetium-99m ethylenedicysteine clearance. European Journal of Nuclear Medicine and Molecular Imaging, 1999, 26, 900-902.	6.4	2
66	Evaluation of renal function in low-dose cyclosporine-treated patients using technetium-99m diaminocyclohexane: a cationic tubular excretion agent. European Journal of Nuclear Medicine and Molecular Imaging, 1998, 25, 1630-1636.	6.4	4
67	Technetium-99m sestamibi uptake in human breast carcinoma cell lines displaying glutathione-associated drug-resistance. European Journal of Nuclear Medicine and Molecular Imaging, 1996, 23, 568-570.	2.1	18
68	Simplified determination of technetium-99m ethylenedicysteine clearance from a single plasma sample: What is the upper normal range?. European Journal of Nuclear Medicine and Molecular Imaging, 1996, 23, 1556-1556.	2.1	4
69	Relationship between the OIH and 99Tcm-EC clearances. Nuclear Medicine Communications, 1994, 15, 1006-1007.	1.1	0